What is Abridge?
Ambient clinical documentation and workflow automation for health systems.
- Category
- Clinical ambient AI
- Headquarters
- Pittsburgh, Pennsylvania
- Founded
- 2018
- Employees
- 500+ reported in 2025
- Total funding
- About $450 million disclosed
- Valuation
- $2.75 billion reported after 2025 Series E
What is Abridge?
Abridge is a clinical ambient ai company headquartered in Pittsburgh, Pennsylvania.
Abridge says its ambient AI is deployed across major health systems and supports clinicians by turning patient conversations into structured clinical notes, orders, and downstream documentation. Reported customers and partners include Mayo Clinic, CHRISTUS Health, Sutter Health, UChicago Medicine, and other large U.S. health systems.
The company was founded in 2018 and remains private. Its public profile is strongest around Ambient clinical documentation and Abridge Inside Epic, while detailed revenue figures are not publicly disclosed.
As of June 2026, the safest public read is that Abridge is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.
What does Abridge offer?
Abridge's public product set centers on Ambient clinical documentation, Abridge Inside Epic, Revenue-cycle documentation support.
- Ambient clinical documentation· Clinical AI
- Abridge Inside Epic· EHR workflow
- Revenue-cycle documentation support· Administrative AI
- Clinical conversation intelligence· Data platform
Sources:Abridge website
How does Abridge make money?
Enterprise software sold to health systems under multi-year commercial agreements; public per-seat pricing is not disclosed.
Enterprise software sold to health systems under multi-year commercial agreements; public per-seat pricing is not disclosed. No public self-serve pricing; procurement is enterprise-contract based.
Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Abridge does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.
The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.
Sources:Abridge websiteForbes AI 50
Who leads Abridge?
Abridge is led by Dr. Shivdev Rao, Co-founder and CEO.
- Dr. Shivdev RaoCo-founder and CEOCo-founder · since 2018Cardiologist and former UPMC executive leading product and clinical strategy.
- Andy WeissmanCo-founderCo-founder · since 2018Union Square Ventures partner and early company builder.
- Tina Shah, MDChief Clinical OfficerExecutivePulmonologist focused on clinician workflow and deployment quality.
- Zachary LiptonChief Scientific OfficerExecutiveML researcher advising clinical AI model development.
How do you contact Abridge's leadership?
Public contact form; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.
Public contact form; no verified personal email pattern foundSources:Abridge website
How much funding has Abridge raised?
Abridge has about $450 million disclosed and is private.
2019: Seed — $15 million, led/backed by UPMC Enterprises and early investors. 2022: Series A — $12.5 million, led/backed by Wittington Ventures. 2023: Series B — $30 million, led/backed by Spark Capital. 2024: Series C — $150 million, led/backed by Lightspeed Venture Partners and Redpoint Ventures. 2025: Series D — $250 million, led/backed by Elad Gil and IVP ($2.75 billion reported valuation).
The latest public valuation/status marker is $2.75 billion reported after 2025 Series E. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.
Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.
How did Abridge get here?
Abridge's timeline runs from its 2018 founding through major financing and product milestones.
- 2018Founded in PittsburghAbridge was created to summarize medical conversations for clinicians and patients.
- 2023Epic integration acceleratedThe company deepened deployments inside EHR workflows.
- 2024Large Series CAbridge raised $150 million to scale health-system rollouts.
- 2025Series D/E reportedAbridge became one of the best-funded ambient clinical AI companies.
- 2025More health-system partnershipsThe company announced deployments with large U.S. provider networks.
Who are Abridge's competitors?
Abridge competes with specialized startups and larger platform companies in clinical ambient ai.
- Ambience HealthcareBroader AI operating system for documentation, coding, and referrals.
- SukiVoice assistant and ambient documentation for clinicians.
- Nuance DAXMicrosoft-owned ambient documentation embedded with major EHRs.
- NablaAI clinical assistant focused on note generation and clinician workflow.
- Heidi HealthFast-growing AI scribe with global clinician adoption.
Sources:Abridge websiteForbes AI 50
Abridge — frequently asked questions
